A
Alvin J. M. Ng
Researcher at St. Vincent's Institute of Medical Research
Publications - 5
Citations - 235
Alvin J. M. Ng is an academic researcher from St. Vincent's Institute of Medical Research. The author has contributed to research in topics: Osteosarcoma & Osteoblast. The author has an hindex of 5, co-authored 5 publications receiving 198 citations. Previous affiliations of Alvin J. M. Ng include St. Vincent's Health System.
Papers
More filters
Journal ArticleDOI
Modeling distinct osteosarcoma subtypes in vivo using Cre:lox and lineage-restricted transgenic shRNA
Anthony J. Mutsaers,Alvin J. M. Ng,Alvin J. M. Ng,Emma Baker,Emma Baker,Megan R. Russell,Alistair M. Chalk,Meaghan Wall,Brain J.J. Liddicoat,Brain J.J. Liddicoat,Patricia W. M. Ho,John Slavin,Ankita Goradia,T. John Martin,T. John Martin,Louise E. Purton,Louise E. Purton,Ross A. Dickins,Carl R. Walkley,Carl R. Walkley +19 more
TL;DR: Through the use of complementary genetic modification strategies, this work has established a model of the most common clinical subtype of osteosarcoma that was not previously represented and more fully recapitulated the clinical spectrum of this cancer.
Journal ArticleDOI
Increased miR-155-5p and reduced miR-148a-3p contribute to the suppression of osteosarcoma cell death
S Bhattacharya,Alistair M. Chalk,Alvin J. M. Ng,Thomas J. Martin,Andrew C.W. Zannettino,Louise E. Purton,Jun Lu,Emma Baker,Carl R. Walkley +8 more
TL;DR: Modulation of these miRNAs was specifically toxic to tumor cells but not normal osteoblasts, raising the possibility that these may be tractable targets for miRNA-based therapies for OS.
Journal ArticleDOI
Activation of PTHrP-cAMP-CREB1 signaling following p53 loss is essential for osteosarcoma initiation and maintenance
Mannu K Walia,Patricia M. W. Ho,Scott Taylor,Alvin J. M. Ng,Alvin J. M. Ng,Ankita Gupte,Alistair M. Chalk,Alistair M. Chalk,Andrew C.W. Zannettino,T. John Martin,T. John Martin,Carl R. Walkley,Carl R. Walkley +12 more
TL;DR: It is demonstrated that elevated Pthlh (Pthrp), cAMP levels and signalling via CREB1 are characteristic of both p53-deficient osteoblasts and OS, and the PTHrP-cAMP-CREB1 axis is identified as an attractive pathway for therapeutic inhibition in OS.
Journal ArticleDOI
Genetically engineered mouse models and human osteosarcoma
Alvin J. M. Ng,Alvin J. M. Ng,Anthony J. Mutsaers,Anthony J. Mutsaers,Anthony J. Mutsaers,Emma Baker,Emma Baker,Carl R. Walkley,Carl R. Walkley +8 more
TL;DR: Recent development of tractable, highly penetrant murine models of osteosarcoma have been a significant advance for efforts to improve the understanding of the genetics of human OS and to provide a high-throughput genetically modifiable platform for preclinical evaluation of new therapeutics.
Journal ArticleDOI
The DNA helicase recql4 is required for normal osteoblast expansion and osteosarcoma formation.
Alvin J. M. Ng,Mannu K Walia,Monique Smeets,Anthony J. Mutsaers,Natalie A. Sims,Louise E. Purton,Nicole C. Walsh,T. John Martin,Carl R. Walkley +8 more
TL;DR: It is proposed that tumor suppression and osteosarcoma susceptibility are most likely a function of mutant, not null, alleles of RECQL4.